ABT-530: Phase II data

Data from 44 patients with chronic HCV genotype 1 infection who failed a prior DAA-containing therapy in the open-label, international Phase II MAGELLAN-1

Read the full 231 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE